Victory Capital Management Inc. Cuts Position in Zoetis Inc. (NYSE:ZTS)

Victory Capital Management Inc. lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 382,044 shares of the company's stock after selling 5,599 shares during the period. Victory Capital Management Inc. owned approximately 0.08% of Zoetis worth $75,404,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Zoetis by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company's stock valued at $2,147,730,000 after purchasing an additional 297,044 shares in the last quarter. Northern Trust Corp grew its stake in shares of Zoetis by 3.3% during the third quarter. Northern Trust Corp now owns 6,143,258 shares of the company's stock worth $1,068,804,000 after buying an additional 196,771 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Zoetis by 3.1% in the 3rd quarter. Royal Bank of Canada now owns 3,026,518 shares of the company's stock valued at $526,553,000 after acquiring an additional 91,713 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Zoetis by 1.4% during the 3rd quarter. Blair William & Co. IL now owns 2,428,509 shares of the company's stock valued at $422,512,000 after acquiring an additional 32,918 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Zoetis by 0.5% during the 3rd quarter. Principal Financial Group Inc. now owns 2,126,090 shares of the company's stock worth $369,736,000 after acquiring an additional 10,153 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 923 shares of the company's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 over the last ninety days. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a "buy" rating in a research note on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an "overweight" rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $195.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday. Finally, Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an "overweight" rating for the company in a research report on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $216.13.

Zoetis Trading Down 0.1 %

ZTS stock traded down $0.16 during midday trading on Friday, hitting $167.07. The stock had a trading volume of 3,007,125 shares, compared to its average volume of 4,607,073. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a market cap of $76.41 billion, a P/E ratio of 32.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. The business has a fifty day moving average price of $168.88 and a two-hundred day moving average price of $178.84. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the previous year, the business earned $1.31 EPS. The firm's revenue was up 9.5% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc. will post 5.78 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. Zoetis's payout ratio is presently 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.